Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Magnevist
Drug ID BADD_D01345
Description A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see pentetic acid), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706)
Indications and Usage For use with magnetic resonance imaging (MRI) in adults, and pediatric patients (2 years of age and older) to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues as well as lesions with abnormal vascularity in the head and neck. Also used to facilitate the visualization of lesions with abnormal vascularity in the body (excluding the heart).
Marketing Status Prescription
ATC Code V08CA01
DrugBank ID DB00789
KEGG ID D01707
MeSH ID D019786
PubChem ID 55466
TTD Drug ID D0RQ2W
NDC Product Code Not Available
Synonyms Gadolinium DTPA | DTPA, Gadolinium | Gadolinium Diethylenetriaminepenta-acetic Acid | Diethylenetriaminepenta-acetic Acid, Gadolinium | Gadolinium Diethylenetriaminepenta acetic Acid | Gadopentetic Acid | Gd-DTPA | Gd DTPA | Gadolinium DTPA Disodium Salt | Magnograf | Magnograf Enteral | Gadopentetate Dimeglumine | Dimeglumine, Gadopentetate | Gadolinium DTPA Dimeglumine Salt | Gadolinium DTPA Dimeglumine | Dimeglumine, Gadolinium DTPA | Magnevist | Magnevist Enteral
Chemical Information
Molecular Formula C28H54GdN5O20
CAS Registry Number 80529-93-7
SMILES CNCC(C(C(C(CO)O)O)O)O.CNCC(C(C(C(CO)O)O)O)O.C(CN(CC(=O)O)CC(=O)[O-])N(CCN(CC(=O) O)CC(=O)[O-])CC(=O)[O-].[Gd+3]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Type IV hypersensitivity reaction10.01.03.022--Not Available
Injection site discomfort12.07.03.019; 08.02.03.018--Not Available
Vasodilation procedure25.03.01.001--Not Available
Angiopathy24.03.02.007--Not Available
Hepatic enzyme increased13.03.01.019--Not Available
Cardiac disorder02.01.01.003--Not Available
Connective tissue disorder15.06.01.006--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Decreased appetite08.01.09.028; 14.03.01.005--
Inner ear disorder04.04.02.002--Not Available
Lacrimal disorder06.08.02.005--Not Available
Blood disorder01.05.01.004--Not Available
Hepatobiliary disease09.01.08.003--Not Available
Renal impairment20.01.03.010--Not Available
Nephrogenic systemic fibrosis15.06.01.009; 10.04.02.007; 23.03.02.012; 20.01.01.004--Not Available
Oropharyngeal discomfort22.02.05.027; 07.05.05.008--Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.004--
Acute kidney injury20.01.03.016--
Lacrimal structural disorder06.06.04.013--Not Available
The 6th Page    First    Pre   6    Total 6 Pages